Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Long-term radioiodine treatment effective in toxic multinodular goiter

03 Jun 2020

Treatment with 15 mCi of radioiodine (RAI) leads to low hypothyroidism rates in adult patients with toxic multinodular goiter (TMNG), with high cure rates and significant volume reduction, according to a study. This effect persists in the long term.

A total of 153 RAI-naïve patients with TMNG were included in this population-based, retrospective analysis conducted in Siena, Italy, with up to 12 years of follow-up. The investigators assessed thyroid functions, antithyroid antibodies, and ultrasound scans before and yearly after RAI. The following outcomes were measured: hyperthyroidism cure, hypothyroidism, volume reduction, nadir and regain, and antibody titre change.

Mean volume reductions 50 percent were observed at 3 years after RAI, with the greatest annual reduction seen during the first year (30±17.8 percent; p<0.001). Majority of the patients (60 percent) achieved their volume nadir 3 to 6 years after RAI. Twenty-two patients had volume regain, but the net reduction was statistically significant as late as 9 years post-RAI (p=0.005).

Mean time to hypothyroidism onset was 2.7±2.4 years and correlated with greater decrease in volume (p=0.01). The number of hyperthyroid patients decreased by nearly 50 percent per year without additional RAI during the first 3 years post-treatment. No statistically significant association was observed between antibody titres and thyroid functions, except for antithyrotropin receptor antibodies and hyperthyroidism (p=0.004).

Of the patients, 61.6 percent were euthyroid, 11 percent hyperthyroid (4.8 percent over), and 27.4 percent hypothyroid (2.7 percent overt) at the end of follow-up. Hyperthyroidism was cured in 89 percent of patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.